Imara attempts to spin weak data into an 'encouraging' result — but investors aren't having it
Imara unveiled data from two subgroups of a Phase IIa trial for its lead compound Wednesday, aiming to conjure up a positive light despite challenges …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.